Saturday, February 29 (21)

9:15 AM–10:15 AM

Current State: Treatment of Cancer Associated Pain (303)

Presentations from three clinicians who provide interventional and medical cancer pain management. Discussion will include novel approaches: including neurosurgical and cryotherapeutic approaches.

Approaches to Cancer Associated Pain

Halena Gazelka

Neurosurgical Approaches to Cancer Associate Pain

Zaman Mirzadeh

Novel Approaches: Cryotherapy and Cancer

Jonathan Morris

Learning Objectives:

  • Describe currently available neurosurgical approaches to cancer associated pain.
  • Determine when cryotherapy may be appropriate for the management of cancer associated pain.
Co-Presenters:

Zaman Mirzadeh

Jonathan Morris

Moderator:

Halena Gazelka

9:15 AM-10:15 AM

Going Deeper into Opioid Deprescribing: Addressing the Concerns of Prescribers and Patients to Optimize Outcomes (302)

This session clarifies the assessment of opioid use behaviors and delivery of individualized, patient-centered opioid reduction strategies across the continuum of opioid use and patient behaviors. The multidisciplinary faculty will summarize the best available evidence and emphasize practical tools rooted in patient safety for optimized patient engagement and success.

Demystifying Opioid Deprescribing Across the Continuum While Providing Individualized, Whole Person Pain Care

Aram Mardian

Addressing Complexities of Opioid Deprescribing with Patient-Centered Approaches: Supportive Psychological Strategies, Low-Cost Technologies, and Self-Management Tools

Beth Darnall

Seamless Integration of Opioid Use Disorder Management in Patients with Chronic Pain

Anita Karnik

Learning Objectives:

  • Use three behavioral strategies to enhance readiness to engage in a collaborative opioid taper.
  • Distinguish opioid use disorder from complex persistent opioid dependence and simple opioid dependence.
  • Describe recent federal cautions related to opioid deprescribing.
Co-Presenters:

Beth Darnall

Anita Karnik

Moderator:

Aram Mardian

9:15 AM–10:15 AM

Neuromodulation Review 1 (301) Featured

In spite of significant advances in SCS technology, there is still a 20% failure rate in long term SCS therapy primarily due to loss of analgesic benefit. Participants will learn what physiological, pharmacological, and electromechanical factors may contribute to this failure rate and what steps can be implemented to improve long term SCS success.

Determinants of SCS Failures: Opioids, Lack of Sustained Analgesia, and SCS Tolerance/Adaptation

Peter Staats, MBA MD

Advances in SCS Pharmacology

Magdalena Anitescu, MD PhD

Programming Approaches to Solve Failure of SCS Analgesia

Lawrence Poree, MD MPH PhD

Learning Objectives:

  • Discuss physiological, pharmacological, and electromechanical factors that may contribute to a failure rate in long term SCS therapy.
  • Identify strategies to improve long-term SCS success.
Subscribe to this RSS feed